Resverlogix: Funding, Investors & Team (Sep 2026)
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-ß Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada.
Resverlogix has raised $4.1M across 2 funding rounds on record, the most recent an undisclosed round of $2.0M announced in May 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Resverlogix Company Profile and Key Stats
Latest funding round on record: May 2026.
Resverlogix Funding Rounds
Resverlogix raised $2.1M in an undisclosed round announced in Feb 2026.
3 months later, an undisclosed round of $2.0M was announced in May 2026.
Resverlogix Founders and Leadership Team
Contact details for the Resverlogix team: 1 has a LinkedIn profile.
Start 14-day free trial →Resverlogix Funding Compared to Other Biotechnology Startups
Resverlogix's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Resverlogix in Biotechnology and Calgary
Companies Similar to Resverlogix
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Resverlogix Funding FAQs
What does Resverlogix do?
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-ß Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada.
How much funding has Resverlogix raised?
Resverlogix has raised $4.1M across 2 rounds on record. The most recent is an undisclosed round of $2.0M announced in May 2026.
When did Resverlogix last raise funding?
Resverlogix's most recent funding round on record is an undisclosed round of $2.0M, announced in May 2026.
Who founded Resverlogix?
FundedIQ lists Don Mccaffrey (Founder), Donald Mccaffrey (Founder) at Resverlogix.
Where is Resverlogix headquartered?
Resverlogix is based in Calgary, Alberta, Canada.
How many employees does Resverlogix have?
Resverlogix is in the 11-50 employee band.
How does Resverlogix's funding compare to other Biotechnology startups?
Resverlogix's latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Resverlogix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Resverlogix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.